These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28394644)

  • 1. BiOSS LIM C: thin-strut cobalt-chromium version of the dedicated bifurcation stent.
    Gil RJ; Bil J; Kaczynski M; Milewski KP
    Expert Rev Med Devices; 2017 Apr; 14(4):279-284. PubMed ID: 28394644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - three-month results.
    Gil RJ; Bil J; Kern A; Pawłowski T
    Kardiol Pol; 2018; 76(2):464-470. PubMed ID: 29192951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent.
    Gil RJ; Pawłowski T; Legutko J; Lesiak M; Witkowski A; Gąsior M; Kern A; Bil J
    Medicine (Baltimore); 2019 Apr; 98(14):e15106. PubMed ID: 30946377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 12-month intravascular ultrasound observations from BiOSS® first-in-man studies.
    Gil RJ; Bil J; Costa RA; Gil KE; Vassiliev D
    Int J Cardiovasc Imaging; 2016 Sep; 32(9):1339-1347. PubMed ID: 27314841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dedicated Bifurcation Drug-eluting Stent BiOSS® - A Novel Device for Coronary Bifurcation Treatment.
    Gil RJ; Vassilev D; Bil J
    Interv Cardiol; 2013 Mar; 8(1):19-22. PubMed ID: 29588746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study.
    Asano T; Kogame N; Onuma Y; Modolo R; Chichareon P; Lefèvre T; Legutko J; Digne F; Morel MA; Serruys PW; Gil RJ
    EuroIntervention; 2020 Oct; 16(8):654-662. PubMed ID: 31543500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.
    Gil RJ; Bil J; Grundeken MJ; Kern A; Iñigo Garcia LA; Vassilev D; Pawłowski T; Formuszewicz R; Dobrzycki S; Wykrzykowska JJ; Serruys PW
    EuroIntervention; 2016 Dec; 12(11):e1404-e1412. PubMed ID: 26600564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up.
    Gil RJ; Bil J; Legutko J; Pawłowski T; Gil KE; Dudek D; Costa RA
    Int J Cardiovasc Imaging; 2018 Mar; 34(3):353-365. PubMed ID: 28965166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies.
    Gil RJ; Bil J; Kern A; Iñigo-Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Mehran R
    Cardiovasc Ther; 2020; 2020():6760205. PubMed ID: 32411301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies.
    Gil RJ; Bil J; Kern A; Iñigo Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Segiet A
    Cardiol J; 2018; 25(3):308-316. PubMed ID: 28840591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the Bifurcation Optimization Stent System in cardiological settings.
    Vassilev DI; Mileva NB; Gil RJ
    Future Cardiol; 2020 Sep; 16(5):397-404. PubMed ID: 32286883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of vascular response to BiOSS LIM C
    Bil J; Gil RJ; Pawlowski T; Milewski KP
    Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28423237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness and safety of the sirolimus-eluting BiOSS LIM® dedicated bifurcation stent in the treatment of distal left main stenosis: an international registry.
    Gil RJ; Bil J; Grundeken MJ; Iñigo Garcia LA; Vassilev D; Kern A; Pawłowski T; Wykrzykowska JJ; Serruys PW
    EuroIntervention; 2016 Nov; 12(10):1246-1254. PubMed ID: 26465375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bifurcation Optimisation Stent System (BiOSS Lim) with sirolimus elution: results from porcine coronary artery model.
    Vassilev D; Gil R; Milewski K
    EuroIntervention; 2011 Sep; 7(5):614-20. PubMed ID: 21930466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BiOSS LIM® Registry.
    Gil RJ; Bil J; Vassiliev D; Iñigo Garcia LA
    J Interv Cardiol; 2015 Feb; 28(1):51-60. PubMed ID: 25689548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus-eluting BiOSS LIM dedicated bifurcation stent in the treatment of unprotected distal left main stenosis.
    Briguori C; Visconti G; Golino M; Focaccio A; Signoriello G
    Catheter Cardiovasc Interv; 2019 Sep; 94(3):323-331. PubMed ID: 30773807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.
    Gil RJ; Bil J; Džavík V; Vassilev D; Kern A; Formuszewicz R; Zalewska-Adamiec M; Dobrzycki S
    Can J Cardiol; 2015 May; 31(5):671-8. PubMed ID: 25828372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-month clinical results from the new cobalt-chromium sirolimus-eluting dedicated bifurcation stent BiOSS LIM C Registry.
    Gil RJ; Kern A; Pawłowski T; Bil J
    Arch Med Sci; 2023; 19(2):324-330. PubMed ID: 37034511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results.
    Gil RJ; Kern A; Bojko K; Gziut-Rudkowska A; Vassilev D; Bil J
    Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.
    Gil RJ; Vassiliev D; Michałek A; Kern A; Formuszewicz R; Dobrzycki S; Lesiak M; Wójcik J; Kardaszewicz P; Lekston A
    Kardiol Pol; 2012; 70(1):45-52. PubMed ID: 22267425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.